LMLaura Magnano

Laura Magnano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Magnano has a total of 483 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CD70 overexpression at diagnosis predicts relapse and supports dual CD19-CD70 CAR T-cell therapy in follicular lymphoma

    by Ferran Araujo-Ayala, Maria Ros, Raluca Alexandru, Judith Mateos-Jaimez, Alba Rodriguez-Garcia, Marta Giménez-Alejandre, María Villalba-Esparza, Pablo Mozas, Guillem Colell, Salut Colell, et al.

    Although first-line immunotherapy achieves remission in most patients with follicular lymphoma (FL), improved biomarkers and therapeutic strategies are required to identify and manage those who relapse. We investigated the immune microenvironment at diagnosis in uniformly treated patients with FL with extended follow-up (>11 years), comparing patients with relapsed disease and those with relapse-free disease. Transcriptomic profiling revealed the enrichment of inflammatory response pathways in relapsed patients, including cytokine overexpression and upregulation of CD70, a molecule implicated in immune activation and inflammation. Multiplex immunofluorescence confirmed CD70 overexpression at diagnosis in tumor cells as well as in CD8+ and CD4+ T follicular helper cells, correlating with inferior progression-free survival. Functional studies demonstrated that CD70+ tumor cells were more proliferative and induced CD70 expression in T cells, suggesting a feed-forward loop sustaining immune activation. To target these cells and enhance current chimeric antigen receptor (CAR) T-cell approaches, we engineered dual CD19-CD70 CAR T cells by cotransducing the CD19 CAR T-cell product ARI-0001 with a CD27-based anti-CD70 CAR. Dual CAR T cells exhibited enhanced in vitro cytotoxicity against patient-derived spheroids of FL, diffuse large B-cell lymphoma, and mantle cell lymphoma. In FL xenograft models, dual CAR T-cell treatment achieved superior disease control compared to monotargeted CAR T cells, inducing complete tumor clearance in the spleen and bone marrow. Collectively, these findings provide a strong preclinical rationale for the clinical development of CD19-CD70 dual CAR T-cell therapy to improve outcomes in high-risk FL and potentially other B-cell non-Hodgkin lymphomas.


  • Open Access

    Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Tuberculosis: A Rare Association With Diagnostic and Therapeutic Challenges

    by Amalia Del Val Talens, Olga Balague, Sonia Rodriguez, Ana del Rio, Andrea Rivero, Pablo Mozas, Juan Correa, Eva Gine, Armando Lopez-Guillermo, Felipe Garcia, et al.

    This case report describes the rare coexistence of pulmonary tuberculosis and pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in a 68-year-old woman. The initial diagnosis of tuberculosis was supported by clinical, radiological, and microbiological findings, and the patient started on standard tuberculostatic therapy. However, the persistence of radiological abnormalities after several months of appropriate treatment, despite improvement in pleural effusion, raised suspicion for an underlying malignancy. Subsequent imaging and histopathological evaluation confirmed the diagnosis of primary pulmonary MALT lymphoma. The patient was successfully treated with immunochemotherapy, achieving complete remission. This case underscores the importance of maintaining a high index of suspicion for alternative or concomitant diagnoses, particularly malignancies, when tuberculosis exhibits an atypical clinical course or when radiological findings fail to resolve as expected. Furthermore, it highlights the need for thorough diagnostic evaluation in patients with persistent pulmonary abnormalities to ensure timely and accurate diagnosis and management.


  • Open Access

    Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target

    by Cèlia Dobaño-López, Juan García Valero, Ferran Araujo-Ayala, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Fabian Arenas, et al.

    Follicular lymphoma (FL), the most common indolent non-Hodgkin lymphoma, constitutes a paradigm of immune tumor microenvironment (TME) contribution to disease onset, progression, and heterogenous clinical outcome. Here we present the first FL-Patient Derived Lymphoma Spheroid (FL-PDLS), including fundamental immune actors and features of TME in FL lymph nodes (LNs). FL-PDLS is organized in disc-shaped 3D structures composed of proliferating B and T cells, together with macrophages with an intermediate M1/M2 phenotype. FL-PDLS recapitulates the most relevant B-cell transcriptional pathways present in FL-LN (proliferation, epigenetic regulation, mTOR, adaptive immune system, among others). The T cell compartment in the FL-PDLS preserves CD4 subsets (follicular helper, regulatory, and follicular regulatory), also encompassing the spectrum of activation/exhaustion phenotypes in CD4 and CD8 populations. Moreover, this system is suitable for chemo and immunotherapy testing, recapitulating results obtained in the clinic. FL-PDLS allowed uncovering that soluble galectin-9 limits rituximab, rituximab, plus nivolumab/TIM-3 antitumoral activities. Blocking galectin-9 improves rituximab efficacy, highlighting galectin-9 as a novel immunotherapeutic target in FL. In conclusion, FL-PDLS maintains the crosstalk between malignant B cells and the immune LN-TME and constitutes a robust and multiplexed pre-clinical tool to perform drug screening in a patient-derived system, advancing toward personalized therapeutic approaches.


  • Open Access

    The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (ARI‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma

    by Núria Martínez‐Cibrián, Valentín Ortiz‐Maldonado, Marta Español‐Rego, Andrea Blázquez, Joan Cid, Miquel Lozano, Laura Magnano, Eva Giné, Juan G. Correa, Pablo Mozas, et al.

    Summary: Varnimcabtagene autoleucel (var‐cel) is an academic anti‐CD19 chimeric antigen receptor (CAR) product used for the treatment of non‐Hodgkin lymphoma (NHL) in the CART19‐BE‐01 trial. Here we report updated outcomes of patients with NHL treated with var‐cel. B‐cell recovery was compared with patients with acute lymphoblastic leukaemia (ALL). Forty‐five patients with NHL were treated. Cytokine release syndrome (any grade) occurred in 84% of patients (4% grade ≥3) and neurotoxicity in 7% (2% grade ≥3). The objective response rate was 73% at Day +100, and the 3‐year duration of response was 56%. The 3‐year progression‐free and overall survival were 40% and 52% respectively. High lactate dehydrogenase was the only covariate with an impact on progression‐free survival. The 3‐year incidence of B‐cell recovery was lower in patients with NHL compared to ALL (25% vs. 60%). In conclusion, in patients with NHL, the toxicity of var‐cel was manageable, while B‐cell recovery was significantly prolonged compared to ALL. This trial was registered as NCT03144583.


  • Open Access

    Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    by Sergio Matarraz, Pilar Leoz, Ana Yeguas-Bermejo, Vincent van der Velden, Anne E. Bras, Jose I. Sánchez Gallego, Quentin Lecrevisse, Rosa Ayala-Bueno, Cristina Teodosio, Ignacio Criado, et al.


  • Open Access

    Correction: ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution

    by Romina Royo, Laura Magnano, Julio Delgado, Sara Ruiz-Gil, Josep Ll. Gelpí, Holger Heyn, Malcom A. Taylor, Tatjana Stankovic, Xose S. Puente, Ferran Nadeu, et al.

  • Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome

    by Ana Muntañola, Pablo Mozas, Santiago Mercadal, Maria Huguet, Sabela Bobillo, Mariana Bastos‐Oreiro, Ana Jiménez‐Ubieto, Jordina Rovira, Andrea Rivero, Carles Tolosa, et al.

    Summary: Although follicular lymphoma (FL) patients relapsing within 24 months after first‐line treatment (POD24) have a poor prognosis, some cases show notable survival after first relapse (SF1R). We aimed to characterize the POD24 FL population and to identify the main prognostic factors at progression. We selected 162 POD24 patients (80F; median age at first relapse 59 years) from a cohort of 1067 grades 1‐3a FL‐treated patients. The remaining 905 patients treated with first‐line immunochemotherapy and diagnosed during the same period were used to compare outcomes in terms of survival. After a median follow‐up of 11.0 years, 96 patients died (10y‐SF1R of 40%). Age over 60 years (p < 0.001), high lactate dehydrogenase (LDH) (p < 0.001), haemoglobin (Hb) less than 120 g/L (p < 0.001), advanced stage (p < 0.001), high‐risk Follicular Lymphoma International Prognostic Index (FLIPI) (p < 0.001), histological transformation (HT) (p < 0.001) and reaching less than complete response (CR) after salvage therapy (p < 0.001), predicted poor SF1R at relapse. In multivariate analysis only high‐risk FLIPI and HT maintained prognostic significance for SF1R. POD24 patients not transformed and with low/intermediate FLIPI at relapse behaved better than the remaining cases. POD24 patients showed an excess mortality of 38% compared to the general population. Although outcome of POD24 FL patients is poor, a considerable group of them (low/intermediate FLIPI and not transformed at first relapse) behave better.


  • Open Access

    ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution

    by Romina Royo, Laura Magnano, Julio Delgado, Sara Ruiz-Gil, Josep Ll. Gelpí, Holger Heyn, Malcom A. Taylor, Tatjana Stankovic, Xose S. Puente, Ferran Nadeu, et al.


  • The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma

    by Pablo Mozas, Andrea Rivero, Alfredo Rivas-Delgado, Ferran Nadeu, Eva Giné, Julio Delgado, Neus Villamor, Elías Campo, Patricia Pérez-Galán, Laura Magnano, et al.

    The Prognostic Nutritional Index (PNI), a parameter combining serum albumin concentration and absolute lymphocyte count, is considered a measure of the nutritional and inflammatory status and the host’s anti-tumor response. We analyzed the clinical characteristics and outcomes according to the PNI of 351 grades 1–3 A FL patients. Forty-one patients (12%) had a PNI ≤45, who were older and showed adverse baseline features. A low PNI was associated with a shorter PFS (only for patients >60 years), and OS (for all patients, 10-year OS, 52% versus 74%, p = 0.0001). The prognostic impact of the PNI on OS was confirmed in a multivariate model for patients >60 years (HR = 3, p = 0.006). In conclusion, the PNI is a readily accessible piece of information that can identify a small subset of FL patients with shorter survival, and it could be an aid to improve the nutritional status of patients prior to treatment initiation.


  • Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma

    by Ivan Dlouhy, Kennosuke Karube, Anna Enjuanes, Itziar Salaverria, Ferran Nadeu, Juan Enric Ramis‐Zaldivar, Juan G. Valero, Alfredo Rivas‐Delgado, Laura Magnano, David Martin‐García, et al.

    Summary: Relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) cases have a poor outcome. Here we analysed clinico‐biological features in 373 DLBCL patients homogeneously treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP), in order to identify variables associated with early failure to treatment (EF), defined as primary refractoriness or relapse within 12 months from diagnosis. In addition to clinical features, mutational status of 106 genes was studied by targeted next‐generation sequencing in 111 cases, copy number alterations in 87, and gene expression profile (GEP) in 39. Ninety‐seven cases (26%) were identified as EF and showed significantly shorter overall survival (OS). Patients with B symptoms, advanced stage, high levels of serum lactate dehydrogenase (LDH) or β2‐microglobulin, low lymphocyte/monocyte ratio and higher Revised International Prognostic Index (R‐IPI) scores, as well as those with BCL2 rearrangements more frequently showed EF, with R‐IPI being the most important in logistic regression. Mutations in NOTCH2, gains in 5p15·33 (TERT), 12q13 (CDK2), 12q14·1 (CDK4) and 12q15 (MDM2) showed predictive importance for EF independently from R‐IPI. GEP studies showed that EF cases were significantly enriched in sets related to cell cycle regulation and inflammatory response, while cases in response showed over‐representation of gene sets related to extra‐cellular matrix and tumour microenvironment.